CD4 T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy.

Cells

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, 3015 GD Rotterdam, The Netherlands.

Published: May 2021

The impaired T cell responses observed in chronic hepatitis B (HBV) patients are considered to contribute to the chronicity of the infection. Research on this impairment has been focused on CD8 T cells because of their cytotoxic effector function; however, CD4 T cells are crucial in the proper development of these long-lasting effector CD8 T cells. In this review, we summarize what is known about CD4 T cells in chronic HBV infection and discuss the importance and opportunities of including CD4 T cells in T cell-directed immunotherapeutic strategies to cure chronic HBV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148211PMC
http://dx.doi.org/10.3390/cells10051114DOI Listing

Publication Analysis

Top Keywords

cd4 cells
16
cells chronic
8
chronic hepatitis
8
cd8 cells
8
chronic hbv
8
cells
5
cd4
4
chronic
4
hepatitis cell-directed
4
cell-directed immunotherapy
4

Similar Publications

New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy.

View Article and Find Full Text PDF

Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial.

View Article and Find Full Text PDF

During nasal polyp (NP) development, activated T cells differentiate into T helper (Th) 1, Th2, and Th17 cells. Additionally, regulatory T cells (Tregs) that have an immune suppressive function are involved in the pathophysiology of chronic rhinosinusitis (CRS) with NP (CRSwNP). Tregs can act as effector cells that produce inflammatory cytokines, such as interleukin (IL)-17A.

View Article and Find Full Text PDF

Background: Epilepsy has a genetic predisposition, yet causal factors and the dynamics of the immune environment in epilepsy are not fully understood.

Methods: We analyzed peripheral blood samples from epilepsy patients, identifying key genes associated with epilepsy risk through Mendelian randomization, using eQTLGen and genome-wide association studies. The peripheral immune environment's composition in epilepsy was explored using CIBERSORT.

View Article and Find Full Text PDF

Background: This study aimed to investigate the prognostic impact of lymph node metastasis (LNM) on patients with colorectal cancer liver metastasis (CRLM) and elucidate the underlying immune mechanisms using multiomics profiling.

Methods: We enrolled patients with CRLM from the US Surveillance, Epidemiology, and End Results (SEER) cohort and a multicenter Chinese cohort, integrating bulk RNA sequencing, single-cell RNA sequencing and proteomics data. The cancer-specific survival (CSS) and immune profiles of the tumor-draining lymph nodes (TDLNs), primary tumors and liver metastasis were compared between patients with and without LNM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!